AIM
XBIT icon

Acrospire Investment Management’s XBiotech XBIT Stock Holding History

Acrospire Investment Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$2K – 2530
2016
Q4 		$2K Sell
200
-200
-50% -$2.66K ﹤0.01% 2133
2016
Q3 		$5K Sell
400
-453
-53% -$6.65K ﹤0.01% 1832
2016
Q2 		$18K Buy
+853
New +$12.3K 0.01% 1568

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
CIA
Capital Impact Advisors Boston, Massachusetts $247M AUM 31.15% 1-Year Est. Return

Acrospire Investment Management's XBIT Position: Q1 2017 in Review

Acrospire Investment Management sold out of XBiotech (XBIT) in Q1 2017, closing a stake of 200 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in XBIT in Q2 2016 and held it in 3 quarters. The position peaked at $18K in Q2 2016. 48 funds tracked by Wall St. Rank hold XBIT as of Q1 2017.

  • Acrospire Investment Management reported no remaining XBiotech position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 200 XBiotech shares in Q1 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in XBiotech in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's XBiotech position peaked at $18K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held XBiotech as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.